The special case of gene therapy pricing

Gene therapy companies that pursue high, one-time payments for their products risk a backlash from payors. A better solution may lie in a pay-for-performance model.

[1]  T. Brennan,et al.  New expensive treatments for hepatitis C infection. , 2014, JAMA.

[2]  Josh Tycko,et al.  Lessons learned from the clinical development and market authorization of Glybera. , 2013, Human gene therapy. Clinical development.

[3]  K. High,et al.  Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. , 2012, Blood.

[4]  Pratima Chowdary,et al.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.

[5]  A. Kesselheim An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences. , 2011, The Milbank quarterly.

[6]  R. Samulski,et al.  Recombinant adeno-associated virus: clinical application and development as a gene-therapy vector. , 2012, Therapeutic delivery.

[7]  S. Pai,et al.  Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[9]  E. Berndt,et al.  Vaccine advance-purchase agreements for low-income countries: practical issues. , 2005, Health affairs.

[10]  Scott Stern,et al.  Innovation Policy and the Economy 2014 , 2009 .

[11]  S. Orkin,et al.  Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases , 2009, Genome Medicine.